转阴后，白蛋白上升、胆红素下降，血小板上升
“Albumin went up; bilirubin went down; platelets went up. They saw clinical improvements, as well. This is a huge advance in HCV among decompensated cirrhotics.”

另一位肝硬化患者使用HARVONI 6周后化验报告，化验项目简写大家都看得懂，不翻译了，
harvoni用药后4周病毒未检测到，即高精阴。最新情况帖主未更新
Got my 6 week blood test results from 1/5/15 back.
Platelets after being in the 70's through most of 2014 was 93,000!
Alk Phos continues to rise 153
Alt continues to drop 31
Ast also continues to drop 23
Billirubin total is up 1.1
All others are within normal range.
__________________
61 y/o F Genotype 1b for 40+ years cirrhosis Started Harvoni on 11/23 for 12 weeks UND 12/22/2014 Ended treatment on Feb 15th.

一个代偿期肝硬化案例
女性 Gender: Female
身高体重 Ht/Wt: 5'9", 165
基因分型 1a
治疗前RNA计数: 348,000
治疗经过：Incivek, interferon 24 weeks, relapsed at first blood draw;
现用治疗方案：SOVALDI+OLYSIO(simeprevir)
治疗时间，12周+2周，医生建议治疗24周
当前病毒检测：未检测到，即高精阴 SVR or Relapse: Currently UND
肝脏状态：失代偿期肝硬化 腹水 Decompensated cirrhosis
其他检查信息没写
见过另一个欧美失代偿期案例：病毒转阴后，ast, alt 恢复正常，其他不记得

索菲+利巴24周，肝性脑病和腹水消失
文章：Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. Presented at ILC 2014

（转帖）EASL 2015]利福昔明联合普萘洛尔有效降低肝硬化门静脉高压
非选择性β受体阻滞剂是唯一公认的降低门静脉压力的治疗方案。然而，其对许多病例的抗门静脉压效果不足，副作用限制了其在临床上的应用。已知Gut细菌易位和内毒素产物会增加肝硬化患者的门静脉压力。第50届欧洲肝脏研究学会（EASL）年会上公布的一项研究分析了添加非吸收性抗生素利福昔明至非选择性β-阻断剂普萘洛尔中的gut净化疗法的疗效
研究方法
我们纳入了2011年1月至2013年7月间的65例晚期肝硬化患者，并随机分配普萘洛尔单药治疗（n= 48）以及普萘洛尔和利福昔明联合治疗（n= 17）。单药治疗组的普萘洛尔剂量最大为320mg/天，目标是使心率（HR）降低25％。联合用药组的普萘洛尔剂量根据心率调整，但最大剂量不超过160mg/天，利福昔明剂量为1200mg/天。对所有患者基线和治疗后3个月后的肝静脉压力梯度（HVPG）进行检测。患者HVPG下降≥20％或低于12mmHg定义为有效。同时也收集平均血压（MBP）和HR，副作用和其他血清学数据。
研究结果
两组门脉压力下降明显（普萘洛尔单药组17.0±3.9mmHg至13.5±4.1mmHg，联合组为16.7±3.6 mmHg至10.9±4.7mmHg，P <0.001）。联合治疗组的HVPG应答率表现较单一治疗组佳（82.4％：50.0％，P = 0.018），联合治疗组的HVPG平均下降值也更大（5.8±3.8mmHg：3.5±3.9mmHg，P = 0.038） ，尤其是联合治疗组的普萘洛尔的平均剂量（152±59.3mg：127.0±32.4mg，P = 0.033）以及HR的下降幅度（20.5±13.0％：7.4±15.5％，P = 0.001）较小。 两组间MBP的下降没有差异（4.4±12.3mmHg：11.7±3.1mmHg，P = 0.695）。单药治疗组8例，联合治疗组2例发现低血压相关性体位性眩晕。
结论
普萘洛尔和利福昔明联合治疗在HVPG下降方面表现出累加效应，且普萘洛尔剂量和副作用均较小，这显示，利福昔明是打破非选择性β受体阻滞剂局限性的一个很好的解决方案。
（原文标题）RIFAXIMIN AND PROPRANOL OL COMBINATION THERAPY IS MORE EFFECTIVE THAN PROPRANOL OL MONOTHERAPY IN THE HEPATIC VENOUS PRESSURE GRADIENT RESPONSE AND PROPRANOL OL DOSE REDUCTION – A PILOT STUDY (Abstrat No G03)

HARVONI 12周、24周+-利巴韦林 与 代偿期肝硬化 初治、经治患者的治愈率

血小板<75 的HARVONI 方案 对肝硬化代偿期 初治与经治患者治愈率的影响: 血小板低影响疗效！
原文：An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin

Harvoni + 利巴韦林 12周和24周方案 治疗 失代偿期肝硬化（CPT B、C级）转阴率

原文：Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study

一个肝硬化经治疗至非肝硬化案例：
治疗3年前：B超回声增粗，诊断：肝硬化。
3年后：B超诊断：无肝硬化表征
还提到有两个病人病毒转阴后肝硬度检测肝纤级别降低1-2个级别
网名：Dee1956
在一个回帖中说：
Hello! I think it all depends on how far along the cirhosis is and it depends on the person
I was dx with the possible transitioning to cirrhosis due to wisps of collagen seen in my biopsy. My ultrasound showed a rough echotexture.
It has been 3 years since I finished tx. In June I had an ultrasound that for the first time said smooth texture, no sign of cirrhosis. I was shocked as I assumed that I would always have the rough echotexture that had been seen since 2008
There have been two members who have come back several years later to tell us that the stage of scarring and fibrosis had reduced a level or two since they finished treating. (Andiamo1 and JimJim)
I know another person who had a high meld score who treated and is now cured and his/her meld score has reduced quite a bit.
I hope the same happens for you.
My doctor explained that once the virus is not attacking your body, healing can occur. Of course that includes eating well, not drinking etc.
Take Care, Dee

一个失代偿期肝硬化案例：
发帖时SVR4，其他回帖中显示：他/她已SVR7，但临床症状仍未改善：
轻度腹水
血小板：41
胆红素高
应该还有门静脉高压
网名：FoxTheRed 2015年8月12日
Today is 4th week after end of therapy. And HCV still undetected. But bilirubin is highj enough ( 2 mg/dL ) and PLT count is low. And mild ascite is in place ( mild ascite without diuretics and no ascite on diuretics )
As i know, in US and EU modern therapy become available much before other countries. So i has a question -
Is here somebody, who got significant improvement in liver functions and portal hypertension after SVR ?
Result from my last blood test
INR - 1.35
total bilirubin - 2.3 mg/dl
albumine - 33
ALT,AST,AlkP,GGT,AFP - norm
PLT - 41

一个肝硬化用药12周复发案例，注意5周病毒检测到，按happywanny经验，应该加治疗周期，即失败在病毒转阴慢、治疗用药时间短，后续治疗方案：医生在向保险公司申请24周harvoni方案，或加利巴韦林）
网名：tmf2 （肝硬化，12周harvoni）
Finished Harvoni 7/7（2015年7月7日完成治疗）,
5th week in still detected （5周仍检测到**所以happy注重12周是对的，应该加疗程）
8th week undetected （8周检测不到）
**three weeks post EOT detected. （治疗结束后3周检测到病毒）
AST 156 ALT 302 up from AST 37 ALT 40. （复发后转氨酶上升）
I am stage 4 Cirrhosis with a Child score A （肝硬化分级：CTP A级）
treatment naive. （初治）
Treatment was 12 weeks Harvoni. （12周 Harvoni方案）
My hopes are dashed. My doctor is attempting to get me approved from my Insurance for 24 weeks of Harvoni possibly with Ribavirin. Is this the best course of action and if they do not approve should I try for the Viekera Pak ? Depressed worried and confused.（医生向保险公司争取Harvoni 24周或加利巴韦林方案）

EASL2015 [url]http://关于代偿与失代偿期肝硬化建议方案见帖子 “欧洲肝病研究会（EASL2015）丙肝1-6型推荐治闻疗方案”56、57楼：http://tieba.baidu.com/p/3871055244?pn=2[/url]，不跟帖了